Year 2017 has been very busy for us with our implantation in Lille on the Eurasanté Park, the installation of HAPIx (our great automation platform from our great partner Molecular Devices), many presentations at many events (BIOFIT Strasbourg, HCA BostonSIBS Zurich, Drug Discovery Liverpool, ELRIGfr Monaco, in-cosmetics Global London, Forum Labo Paris, etc.), the strengthening of our scientific partnerships, the internalization of BIOMIMESYS technology and, of course, the development of our amazing team ! We are also preparing a great 2018 year … but for the moment, we wish you great Christmas holidays, full of joy and peaceful ! See you next year 🙂


We were at Biofit 2017 in Strasbourg a few weeks ago and this edition has been a real success, with more than 1000 delegates from 30 countries ! We were very glad to present our new HAPIx platform and we have extended our partnerships on our core R&D programs !

We especially want to thank Eurasante for the invitation on its booth. An ideal place to present a virtual reality tour of our laboratories as you see on the picture ! IT was nice to be close to our collegues from Sencet, who work on the characterization of circulating tumor cells using Silicon Nanotweezer (SNT) technology.

We also would like to congratulate Vaxinano for the prize in the Start-up Slams ! If you want to discover this technology, visit the company website. There were many interesting conferences so it’s hard to select only some of them, but we particularly appreciated the panel lead by John Mack (from Pharma Marketing Blog) about collaboration between academic institution and spin-off.

If you want more details about the two days of Biofit 2017, look at these videos from Future Worlds (startup network from the University of Southampton), it’s really amazing !

Next year, Biofit 2018 will take place in Lille and, of course, we will be there… See you next year !


It’s very interesting to show that, at HCS Pharma, we work on many of the most exciting medical technologies identified by Dr. Bertalan Mesko on his blog, Of course, precision medicine is the most important for us, because we see here extraordinary tools to treat cancer and neurodegenerative diseases (“instead of canons, we start using sniper rifles.”)

But two other fields seem really promising. The 3D bioprinting for exemple will give us the possibility to create relevant in vitro models of living tissues. We also work to integrate IA deep learning in our HCS processes. It will be a major method to find phenotypic actions of futur drugs.

2016 was a rich year for medical technology. Virtual Reality. Augmented Reality. Smart algorithms analysing wearable data. Amazing technologies arrived in our lives and on the market almost every day. And it will not stop in the coming year.

Source: The Most Exciting Medical Technologies of 2017 – The Medical Futurist

This picture is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported license – Source

2016 ended very well for HCS Pharma, with a fundraising finalized with the regional funds of the French country “Hauts de France”. This fundraising allows us to settle a new location in Lille, closest to the researchers and clinicians of the centers of excellence on neurodegenerative diseases and oncology.  We already have collaborative research projects with these teams and we are going to strengthen it. Our team will also grow throughout the year with different recruitments planned. In the short run, the acquisition of a complete robotic platform will also be realized, to allow us to increase our throughput. If you want more information, feel free to contact us !

Year 2016 is ending with very good results for HCS Pharma, with a nice and motivated team, the effective launch of partnerships with the “Insitut du Thorax” in Nantes and Inserm U991 in Rennes, and customers partners that reiterate their trust. 2017 will be the year of our strengthening, with new labs in Lille, completing those of Rennes. We will thus enhance our collaborations and know-how in the fields of neurosciences and cancer research. The installation in Lille will also give us the in-house ability to screen full compound libraries, either on 2D cell cultures or 3D microtissues.
Goodbye 2016, welcome 2017 ! 

%d bloggers like this: